Ducharme Jeremy B, Carelock Madison E, Schonk Martin M, Al-Zaeed Nour M, Zhang Weizhou, Judge Sarah M, Judge Andrew R
Department of Physical Therapy, University of Florida, Gainesville, Florida, United States.
Myology Institute, University of Florida, Gainesville, Florida, United States.
Am J Physiol Cell Physiol. 2025 Apr 1;328(4):C1125-C1134. doi: 10.1152/ajpcell.00816.2024. Epub 2025 Feb 24.
Cancer cachexia is the involuntary loss of body and skeletal muscle mass, which negatively impacts physical function, quality of life, treatment tolerance, and survival. Skeletal muscles of cachectic people and mice with pancreatic tumors also exhibit skeletal muscle damage, nonresolute immune cell infiltration, and impaired regeneration. These phenotypes may be influenced by the accumulation of senescent cells, which secrete factors detrimental to skeletal muscle health. However, there is currently no comprehensive research on the senescent cell accumulation in the skeletal muscle of tumor-bearing hosts, with or without chemotherapy. To address this gap, we cross-referenced the SenMayo panel of 125 senescence-related genes with our RNA-seq dataset in mouse skeletal muscle during the initiation and progression of cancer cachexia, which revealed a differential expression of 39 genes at precachexia, 64 genes at cachexia onset, and 72 genes when cachexia is severe. Since p16 is a canonical marker of senescence, we subsequently orthotopically injected p16-tdTomato reporter mice with murine KPC pancreatic cancer cells and treated a subset of mice with chemotherapy. At experimental endpoint, when KPC treatment-naïve mice were cachectic, we observed an increased accumulation of p16+ cells, along with increased mRNA levels of hallmark senescence markers (, , senescent-associated-β-galactosidase), which were exacerbated by chemotherapy. Finally, we demonstrate an increase in in the muscle of cachectic patients with pancreatic cancer, which associated with cachexia severity. These findings suggest that senescent cells accumulate in skeletal muscle of cachectic pancreatic tumor-bearing hosts and that chemotherapy can exacerbate this accumulation. To the best of our knowledge, this study is the first to investigate senescent cell accumulation in skeletal muscle of tumor-bearing hosts and its exacerbation by chemotherapy. Our findings identify an accumulation of senescent cells and reveal a senescence-related transcriptional program in skeletal muscle during the initiation and progression of cancer cachexia that is exacerbated by chemotherapy treatment. This highlights a novel potential therapeutic mechanism that can be targeted for the prevention of cancer-induced muscle pathologies.
癌症恶病质是身体和骨骼肌质量的非自愿性丧失,对身体功能、生活质量、治疗耐受性和生存率产生负面影响。患有胰腺癌的恶病质患者和小鼠的骨骼肌也表现出骨骼肌损伤、免疫细胞浸润不消退以及再生受损。这些表型可能受衰老细胞积累的影响,衰老细胞会分泌对骨骼肌健康有害的因子。然而,目前对于荷瘤宿主骨骼肌中衰老细胞积累的情况,无论是否进行化疗,都缺乏全面的研究。为了填补这一空白,我们将包含125个衰老相关基因的SenMayo基因集与我们在癌症恶病质发生和发展过程中小鼠骨骼肌的RNA测序数据集进行了交叉对照,结果显示在恶病质前期有39个基因差异表达,恶病质开始时有64个基因差异表达,恶病质严重时则有72个基因差异表达。由于p16是衰老的经典标志物,我们随后将携带p16-tdTomato报告基因的小鼠原位注射鼠源KPC胰腺癌细胞,并对一部分小鼠进行化疗。在实验终点,当未接受KPC治疗的小鼠出现恶病质时,我们观察到p16+细胞的积累增加,同时标志性衰老标志物(p16、p21、衰老相关β-半乳糖苷酶)的mRNA水平也增加,化疗会加剧这种情况。最后,我们证明胰腺癌恶病质患者肌肉中的p16增加,且与恶病质严重程度相关。这些发现表明,衰老细胞在荷瘤胰腺癌宿主的骨骼肌中积累,化疗会加剧这种积累。据我们所知,本研究是首次调查荷瘤宿主骨骼肌中衰老细胞的积累情况及其化疗加剧效应。我们的研究结果确定了衰老细胞的积累,并揭示了癌症恶病质发生和发展过程中骨骼肌中与衰老相关的转录程序,化疗会加剧这一程序。这突出了一种新的潜在治疗机制,可作为预防癌症诱导的肌肉病变的靶点。